IPO Archives

News and Trends 26 Dec 2016

The Largest Deals, Fundraising and Exits of 2016 in European Biotech

Curious about which technologies have attracted the most cash in biotech finance this year? Here’s a list of the most impressive cash movements of 2016 in Europe. Believe it or not, 2016 has been the worst year for biotech finance in a decade. The political scene has become unfavorable for British biotech after Brexit, and the uncertainty raised by […]

December 26, 2016 - 5 minutesmins - By Clara Rodríguez Fernández

Screenshot 2016 12 07 at 3.46.36 PM e1481122126679

News and Trends 15 Dec 2016

UPDATE: European Stem Cell Therapy Pioneer goes for €34M IPO

TiGenix is entering the Nasdaq with an IPO aimed at funding clinical trials. Will this move allow the company to make it through clinical trials? TiGenix is a Belgian company behind ChondroCellect, the first cell therapy approved on the European market. The biotech has now announced a Nasdaq IPO that aims to raise €39.8M in order to fund […]

December 15, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 20 Oct 2016

CRISPR Thx’ surprisingly low IPO… why are Investors Discouraged?

Troubled waters in the CRISPR field: CRISPR Therapeutics’ IPO hits an unexpectedly low price. It seems that the investors are starting to switch from hype to uncertainty, but why now? CRISPR Therapeutics has just announced the results of a surprisingly low IPO: €51M ($56M), way lower than its €80M target. Its competitors in the therapeutics CRISPR field, Editas […]

October 20, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 30 Sep 2016

Interview: GeNeuro’s CFO explains its Unique Multiple Sclerosis Treatment

GeNeuro is developing a unique treatment for multiple sclerosis. We interviewed Miguel Payro, the company’s CFO, who explained its advantageous position against big pharma. GeNeuro raised €33M in its Euronext IPO in April and is currently competing against giants like Novartis and Biogen. Despite 2016’s dubious honor as “the worst year for IPO in 20 years”, this Switzerland-based company has managed to go […]

September 30, 2016 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 26 Sep 2016

UPDATE: AC Immune rakes in €52.5M IPO for assault on Alzheimers

It’s not the $700M headlines imply, but AC Immune is winding up to make a splashy IPO of €52.5M to establish itself in the Alzheimer’s Disease space. You might have read about AC Immune‘s ‘$700M IPO’ and thought, “gee, that can’t be right – that sum is roughly half of the total from all European companies […]

September 26, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 12 Sep 2016

CRISPR Therapeutics applies to go Public in another Massive IPO

The wait is over: CRISPR Therapeutics has turned up the heat on its rivals with an IPO filing of €80M, but this figure could be a lowball. Everyone saw it coming – the only question was, when would CRISPR Therapeutics file for an IPO? News arrived today that the company had finally applied to the US […]

September 12, 2016 - 3 minutesmins - By Evelyn Warner

geneuro euronext multiple sclerosis biotech

News and Trends 16 Apr 2016

First Euronext Biotech IPO of 2016 is Swiss, and for Multiple Sclerosis!

We last wrote about GeNeuro in January, when they announced the launch of an IPO for their Multiple Sclerosis phase IIb trial. Now, as of yesterday they are listed on the Euronext Paris market. GeNeuro (in Geneva) is developing therapies and diagnostic tools for diseases associated with the expression of the human endogenous retrovirus MSRV, such […]

April 16, 2016 - 2 minutesmins - By Dani Bancroft

europe biotech ey finance growth pharma industry 2016

News and Trends 12 Apr 2016

How was the Biotech Financial World in 2015? Unprecedented!

Biotech is still breaking funding records. A new report by EY provides an interesting analysis of how Biotech is doing, globally and in Europe. Although 2015 was the best for Biotech yet, but there is a slowdown coming – that’s the gist of EY’s recent report: ‘Beyond borders 2016: Biotech financing‘. This well-known auditing and […]

April 12, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 21 Mar 2016

This CEO was responsible for the Only German Biotech IPO in 2015…

Whilst at the Sachs conference last week, I had the chance to meet with Oliver Schacht, the CEO of Curetis. It’s the only German Biotech which went public last year and this was a good enough reason to have a chat (the company is also really interesting, obviously). Curetis is based in Stuttgart in the […]

March 21, 2016 - 1 minutemin - By Philip Hemme

News and Trends 26 Oct 2015

Financial Storm approaching? EU Biotechs start postponing their IPOs in London …

Biotech financing beats record over record since beginning of 2014. Financing has never been as high in Europe (though of course, we know this has always been the case for the US). Just look at Neil Woodford, famous british investor who raised €1.1Bn for its fund and injected it in many companies like Immuncore (2nd biggest VC round […]

October 26, 2015 - 3 minutesmins - By Philip Hemme

News and Trends 6 Aug 2015

Here are 7 Biotech Stories you Must Read During the Holidays

The Holidays are a perfect time to enjoy the sun and relax peacefully on the beach but it’s also a great time to read inspiring stories about your favorite topic, Biotechs! For your delight, we bring you the most read biotech stories of this year. Discover or re-discover them and enjoy! January – The CRISPR’s Therapeutical revolution Six […]

August 6, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 29 Jul 2015

Erytech follows the path of DBV and Cellectis into the US stock exchange

Erytech Pharma, developer of an innovative ‘tumor starvation’ treatment, today announced that it plans to conduct a registered initial public offering in the United States and thus, plays in the major league with its French fellows DBV and Cellectis. It’s definitely the last trend in Biotech! European companies are queuing up to enter the US stock market. In […]

July 29, 2015 - 2 minutesmins - By Joachim Eeckhout

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

IPO

The Largest Deals, Fundraising and Exits of 2016 in European Biotech

UPDATE: European Stem Cell Therapy Pioneer goes for €34M IPO

CRISPR Thx’ surprisingly low IPO… why are Investors Discouraged?

Interview: GeNeuro’s CFO explains its Unique Multiple Sclerosis Treatment

UPDATE: AC Immune rakes in €52.5M IPO for assault on Alzheimers

CRISPR Therapeutics applies to go Public in another Massive IPO

First Euronext Biotech IPO of 2016 is Swiss, and for Multiple Sclerosis!

How was the Biotech Financial World in 2015? Unprecedented!

This CEO was responsible for the Only German Biotech IPO in 2015…

Financial Storm approaching? EU Biotechs start postponing their IPOs in London …

Here are 7 Biotech Stories you Must Read During the Holidays

Erytech follows the path of DBV and Cellectis into the US stock exchange

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!